Corrias Maria Valeria, Gambini Claudio, Gregorio Andrea, Croce Michela, Barisione Gaia, Cossu Claudia, Rossello Armando, Ferrini Silvano, Fabbi Marina
Laboratory of Oncology, Gaslini Institute, Genoa, Italy.
Cell Oncol. 2010;32(1-2):77-86. doi: 10.3233/CLO-2009-0494.
The Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166), involved in nervous system development, has been linked to tumor progression and metastasis in several tumors. No information is available on ALCAM expression in neuroblastoma, a childhood neoplasia originating from the sympathetic nervous system.
ALCAM expression was analysed by immunofluorescence and immunohistochemistry on differentiated neuroblastoma cell lines and on archival specimens of stroma-poor, not MYCN amplified, resectable neuroblastoma tumors, respectively.
ALCAM is variously expressed in neuroblastoma cell lines, is shed by metalloproteases and is cleaved by ADAM17/TACE in vitro. ALCAM is expressed in neuroblastoma primary tumors with diverse patterns of subcellular localization and is highly expressed in the neuropil area in a subgroup of cases. Tumor specimens showing high expression of ALCAM at the membrane of the neuroblast body or low levels in the neuropil area are associated with relapse (P=0.044 and P<0.0001, respectively). In vitro differentiated neuroblastoma cells show strong ALCAM expression on neurites, suggesting that ALCAM expression in the neuropil is related to a differentiated phenotype.
Assessment of ALCAM localization by immunohistochemistry may help to identify patients who, in the absence of negative prognostic factors, are at risk of relapse and require a more careful follow-up.
活化白细胞细胞黏附分子(ALCAM/CD166)参与神经系统发育,已被证明与多种肿瘤的进展和转移有关。目前尚无关于神经母细胞瘤(一种起源于交感神经系统的儿童肿瘤)中ALCAM表达的相关信息。
分别通过免疫荧光和免疫组织化学方法,对分化的神经母细胞瘤细胞系以及基质少、无MYCN扩增、可切除的神经母细胞瘤肿瘤存档标本中的ALCAM表达进行分析。
ALCAM在神经母细胞瘤细胞系中呈多种表达形式,可被金属蛋白酶释放,并在体外被ADAM17/TACE切割。ALCAM在神经母细胞瘤原发肿瘤中表达,亚细胞定位模式多样,在部分病例的神经毡区域高表达。神经母细胞体膜上ALCAM高表达或神经毡区域低表达的肿瘤标本与复发相关(分别为P = 0.044和P < 0.0001)。体外分化的神经母细胞瘤细胞在神经突上显示出强烈的ALCAM表达,提示神经毡中ALCAM的表达与分化表型相关。
通过免疫组织化学评估ALCAM定位,可能有助于识别那些在没有不良预后因素的情况下有复发风险且需要更密切随访的患者。